Navigation Links
Isis Pharmaceuticals to Present at the 14th Annual Bank of America Merrill Lynch Health Care Conference
Date:5/3/2011

CARLSBAD, Calif., May 3, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at Bank of America  Merrill Lynch's 14th Annual Health Care Conference on Tuesday, May 10, 2011 at 1:40 p.m. PT at the Encore at the Wynn in Las Vegas.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Optimer Pharmaceuticals Expands Senior Management Team
2. Avanir Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference
3. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
4. Amira Pharmaceuticals Announces Completion of Phase 1 Clinical Study for AM152, A Novel LPA1 Receptor Antagonist
5. Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction
6. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
7. Valeant Pharmaceuticals to Announce 2011 First Quarter Results on May 9, 2011
8. Optimer Pharmaceuticals to Present at May 2011 Investor Conferences
9. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
10. Inovio Pharmaceuticals to Present at Investor Conferences
11. Endo Pharmaceuticals Reports Strong First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with abnormal auto-immune responses and inflammation, has selected the ... large scale GMP clinical and pre-commercial supplies of A-623, ... of autoimmune diseases. "Establishing a rapid and ...
... Reportlinker.com announces that a new market research report ... 2010 Pharmaceuticals Research Review ... slowdown has accentuated the fault lines already dividing ... large pharma companies, coupled with the patent expiration ...
Cached Medicine Technology:Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 2Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 3Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Anthera's Investigational Novel Peptibody Agent 4Reportlinker Adds 2010 Pharmaceuticals Research Review 2Reportlinker Adds 2010 Pharmaceuticals Research Review 3Reportlinker Adds 2010 Pharmaceuticals Research Review 4Reportlinker Adds 2010 Pharmaceuticals Research Review 5Reportlinker Adds 2010 Pharmaceuticals Research Review 6Reportlinker Adds 2010 Pharmaceuticals Research Review 7Reportlinker Adds 2010 Pharmaceuticals Research Review 8Reportlinker Adds 2010 Pharmaceuticals Research Review 9Reportlinker Adds 2010 Pharmaceuticals Research Review 10Reportlinker Adds 2010 Pharmaceuticals Research Review 11Reportlinker Adds 2010 Pharmaceuticals Research Review 12Reportlinker Adds 2010 Pharmaceuticals Research Review 13Reportlinker Adds 2010 Pharmaceuticals Research Review 14
(Date:7/10/2014)... Thompson HealthDay Reporter THURSDAY, ... wars that break out regularly between outspoken celebrities or loudmouth ... own relationship, a new study suggests. High amounts of ... if the couple is in a long-term relationship, according to ... In turn, that friction can lead to cheating and breakups, ...
(Date:7/10/2014)... responders felt better prepared to respond to an active ... a new study in the journal Prehospital and ... specifically examine the EMS provider comfort level with respect ... yet been neutralized or working with law enforcement personnel ... High School shooting, the Virginia Tech campus shooting, the ...
(Date:7/10/2014)... amount of alcoholic beverages consumed, even for light-to-moderate ... risk of coronary heart disease, lower body mass ... new multi-center study published in The BMJ ... Medicine at the University of Pennsylvania. The latest ... that consuming light-to-moderate amounts of alcohol (0.6-0.8 fluid ...
(Date:7/10/2014)... The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. , ... unique model developed at UH to enhance care for ... demonstrated need for high health care utilization. ...
(Date:7/10/2014)... imaging far outweigh the risks when children receive The ... Radiation Dose. However, overuse and misuse of imaging change ... collaborative effort to ensure a national protocol is put ... Journal of Patient Safety , calls for the American ... Commission, and the Centers for Medicare & Medicaid Services ...
Breaking Medicine News(10 mins):Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3Health News:Active shooter training increases comfort level of emergency responders 2Health News:New study shows drinking alcohol provides no heart health benefit 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 2Health News:UH Case Medical Center awarded $4.7 million grant from HHS 3Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2
... Analysis of a drug regimen approved by the F.D.A. ... (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) ... received this regimen did not have improved survival compared to ... alone, according to a study in the April 18 issue ...
... The Prospective Surveillance Model, an innovative new model of breast ... American Cancer Society,s journal, Cancer released on April ... by women with breast cancer and offers hope for an ... through rehabilitation and exercise. APTA members Nicole ...
... (Toronto) People with an opioid addiction had the highest risk ... drugs, according to a new study by the Centre for ... on opioids, the risk of death was 5.71 times higher ... gender and race. Those with methamphetamine use disorders were next ...
... plays an integral role in physical health dates back to ... referred to as the founder of medicine, wrote "natural ... University of Missouri team has tapped into the science and ... award-winning program. Called "Taking Care of You: Body-Mind-Spirit," ...
... undergoing chemoradiation therapy (CRT) for head and neck cancer, ... short-term improvement in swallowing function; however, there were no ... and controls at nine or 12 months following treatment, ... Archives of Otolaryngology Head & Neck Surgery ...
... MONDAY, April 16 (HealthDay News) -- Tattoos and body piercings ... in western societies, but a new study in France found ... than their peers. In the study, researchers asked ... they left bars and other drinking establishments. The readings showed ...
Cached Medicine News:Health News:Study examines drug regimen for the treatment of non-small cell lung cancer among older patients 2Health News:Study examines drug regimen for the treatment of non-small cell lung cancer among older patients 3Health News:Model for breast cancer rehab featured in supplement to ACS journal, Cancer 2Health News:Opioids associated with highest risk of death 2Health News:MU receives national award for using mind-body approach to improve health 2Health News:Swallowing exercises linked with short-term improvement among patients with head and neck cancer 2Health News:Tattoos, Piercings Tied to Heavier Drinking in French Study 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: